16
total announcements
543434.BO · 15 min delayed
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the 18th Annual General Meeting (AGM) to be held on September 24, 2026, through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The company has also announced a one-time Specimen Window for the redemption of shareholder deeds or Physical Shares that were lodged prior to April 1, 2019.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the record date for determining members eligible to receive dividend for FY 2025-26. The company has recommended a final dividend of Re. 1.00/- per equity share of Rs. 2/- each, subject to approval of members at the Annual General Meeting scheduled to be held on September 24, 2026. The dividend will be paid within 30 days to the members whose names appear in the Register of Members of the Company and/or Register of Beneficial Owners maintained by the Depositories as on the record date.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the voting results of its postal ballot, where the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three consecutive years was passed with a requisite majority. The voting results show that all shareholders, including promoters and public institutions, voted in favor of the resolution.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the voting results of its postal ballot, where the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three consecutive years has been passed with the requisite majority.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the availability of the earnings call transcript for Q1 FY '27, with revenue at Rs. 190 crores, a 31% year-on-year growth, and EBITDA at Rs. 47 crores, a decline of 8.1% year-on-year.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the availability of the audio recording of its earnings call held on August 14, 2026, discussing the company's operational and financial performance for the quarter ended June 30, 2026. The recording is available on the company's website.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a total income from operations of ₹4,791.67 crore and a net profit of ₹1,184 crore.
Supriya Lifescience Ltd
Supriya Lifescience Ltd reported a 31% YoY revenue growth in Q1 FY27, with revenue of Rs 189.75 crore, and a PAT of Rs 24.04 crore. The company's EBITDA margin declined to 25.0% in Q1 FY27 from 35.6% in Q1 FY26.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has released its Q1 FY27 investor presentation, showcasing a 31% YoY increase in revenue, 8% YoY increase in EBITDA, and 14% YoY increase in PBT. The company's PAT has seen a 31% YoY growth. The presentation highlights the company's business mix revenue contribution by region and therapy, with a focus on the top therapeutic areas.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹1,897.47 crore, ₹2,765.28 crore, ₹1,450.74 crore, and ₹8,278.01 crore for the respective periods.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹1,897.47 crore.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced an earnings call to discuss its unaudited financial results for the quarter ended June 30, 2026. The call is scheduled for August 14, 2026, at 11:00 A.M. IST. The company has also provided details for pre-registration and dial-in for the call.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has scheduled a board meeting on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The trading window for dealing in the company's securities by designated persons and their immediate relatives will be closed from July 1, 2026, till 48 hours after the declaration of the unaudited financial results.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced the publication of a postal ballot notice in newspapers, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice relates to the distribution of income under the Kotak Arbitrage Fund and the record date for the same is July 24, 2026.
Supriya Lifescience Ltd
Supriya Lifescience Ltd has announced a postal ballot notice for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Special Key Managerial Personnel for a term of three consecutive years.
Supriya Lifescience Ltd
Supriya Lifescience Ltd issued an email communication to its shareholders detailing the tax deduction at source (TDS) provisions applicable to the final dividend of Re. 1.00/- per equity share for FY2025-26, which was recommended by the board. The communication explains that dividends are taxable in the hands of shareholders and the company will deduct TDS based on residential status and submitted documents. It outlines applicable TDS rates for resident shareholders, including potential exemptions for individuals providing Form 15G/15H if the total dividend is under Rs. 10,000, and emphasizes the need for a valid and operative PAN linked with Aadhaar to ensure appropriate tax deduction.